Literature DB >> 13236091

[Chlorpromazine treatment; side effects and complications].

E GIACOBINI, B LASSENIUS.   

Abstract

Entities:  

Keywords:  CHLORPROMAZINE/injurious effects

Mesh:

Substances:

Year:  1954        PMID: 13236091

Source DB:  PubMed          Journal:  Nord Med        ISSN: 0029-1420


× No keyword cloud information.
  8 in total

1.  Fatal agranulocytosis during treatment with chlorpromazine.

Authors:  J R TASKER
Journal:  Br Med J       Date:  1955-04-16

2.  Agranulocytosis and severe leucopenia after chlorpromazine hydrochloride.

Authors:  J C ADAMS; K D CORTI; Q J HOBSON
Journal:  Br Med J       Date:  1956-05-12

3.  The occurrence of epileptic fits in leucotomized patients receiving chlorpromazine therapy.

Authors:  D W LIDDELL; N RETTERSTOL
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-05       Impact factor: 10.154

4.  Some observations on the use of the phenothiazine derivatives in anaesthesia and their mode of action, with special reference to chlorpromazine.

Authors:  D A B HOPKIN
Journal:  Can Med Assoc J       Date:  1956-09-15       Impact factor: 8.262

5.  Non-thrombocytopenic purpura after administration of chlorpromazine hydrochloride.

Authors:  E MARLEY
Journal:  Br Med J       Date:  1955-11-05

6.  Eye and skin changes in psychiatric patients treated with chlorpromazine.

Authors:  M B Mathalone
Journal:  Br J Ophthalmol       Date:  1967-02       Impact factor: 4.638

7.  Clozapine-induced agranulocytosis: a situation report up to August 1976.

Authors:  B Anderman; R W Griffith
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

8.  The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: two cohorts, 1875-1924 & 1994-2006 compared.

Authors:  Joanna Le Noury; Afshan Khan; Margaret Harris; Winnie Wong; Dawn Williams; Tony Roberts; Richard Tranter; David Healy
Journal:  BMC Psychiatry       Date:  2008-08-07       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.